Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Solana price shows strength, key support level at $67, key resistance levels at $78 and $100

Solana price shows strength, key support level at $67, key resistance levels at $78 and $100

Bitget2023/12/15 09:10

According to CryptoPotato, despite recent pullbacks, Solana remains strong. The key support level is $67, and the key resistance levels are $78 and $100. Solana seems ready to break through and turn the resistance at $78 into support. If this happens, the cryptocurrency is more likely to reach a three-digit valuation. The support at $67 successfully resisted selling on Monday, with buyers returning and pushing the price back towards the key resistance level. This indicates that market corrections are relatively shallow and quickly bought up. Although the price appears poised for further gains, the 3-day RSI shows a different situation. Since mid-November, RSI has been making lower highs, which requires caution. Based on RSI analysis, momentum may reverse. SOL still leans towards bullishness. In terms of short-term predictions for SOL's price, there may be conflicts with the next key target of $100 after breaking through $78. Such an impact would require an uninterrupted dominance by the bull market.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51